• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024

    6/10/24 8:00:00 AM ET
    $AIM
    $AREC
    $CNSP
    $GRI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Coal Mining
    Energy
    Get the next $AIM alert in real time by email

    - Live video webcast presentations with Q&A

    - Preliminary schedule of participating companies now available at www.virtualinvestorco.com

    FRENCHTOWN, NJ / ACCESSWIRE / June 10, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Pitch Conference on June 17-18, 2024.

    For the event, participating companies will provide their "elevator pitch" and outline upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as time allows.

    The current schedule of participating companies is as follows:

    Monday, June 17

    • 10:00 AM ET: Adolore BioTherapeutics, Inc. (Private) - Webcast
    • 11:00 AM ET: CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Webcast
    • 12:00 PM ET: Palisade Bio, Inc. (NASDAQ:PALI) - Webcast
    • 1:00 PM ET: AIM ImmunoTech Inc. (NYSE:AIM) - Webcast
    • 4:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) - Webcast

    Tuesday, June 18

    • 10:00 AM ET: Royalty Management Holding Corporation (NASDAQ:RMCO) - Webcast
    • 11:00 AM ET: GRI Bio, Inc. (NASDAQ:GRI) - Webcast
    • 12:00 PM ET: Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Webcast
    • 1:00 PM ET: American Resources Corporation (NASDAQ:AREC) - Webcast
    • 3:00 PM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - Webcast

    All investors and interested parties can access the event schedule and individual company webcast details at www.virtualinvestorco.com. Webcast replays will be made available shortly after the conclusion of the live event and will be accessible for 90 days.

    To access all Virtual Investor events, visit www.virtualinvestorco.com.

    About JTC Team

    JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

    Contact:

    Jenene Thomas
    JTC Team, LLC
    T: +1 (833) 475-8247
    [email protected]

    SOURCE: JTC Team, LLC



    View the original press release on accesswire.com

    Get the next $AIM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIM
    $AREC
    $CNSP
    $GRI

    CompanyDatePrice TargetRatingAnalyst
    American Resources Corporation
    $AREC
    9/15/2025$6.00Buy
    D. Boral Capital
    Outlook Therapeutics Inc.
    $OTLK
    8/29/2025Buy → Neutral
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    8/28/2025Buy → Neutral
    Guggenheim
    Moleculin Biotech Inc.
    $MBRX
    6/9/2025$4.00Buy
    H.C. Wainwright
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    12/2/2024Buy → Neutral
    Chardan Capital Markets
    Outlook Therapeutics Inc.
    $OTLK
    3/27/2024$50.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $AIM
    $AREC
    $CNSP
    $GRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Outlook Therapeutics Provides Update on Type A Meeting with FDA

    ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.  (NASDAQ: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed the Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. Based on the discussion with the FDA, Outlook Therapeutics expects to resubmit its BLA before the end of calendar year 2025, after revie

    9/29/25 8:45:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

    Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company's special meeting of stockholders held on September 26, 2025 at 10:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, due to lack of the required quorum. A quorum consists of one-third of the outstanding shares of the Company's common stock entitled to vote at the special meeting. There were fewer than one-third of outstanding shares of the Company'

    9/26/25 4:05:00 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

    Patent supports AIM's strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical market globally, with oncology as the fastest-growing therapeutic area OCALA, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AIM) ("AIM" or the "Company") today announced that the Japan Patent Office has issued a patent covering the Company's proprietary use of Ampligen® (Rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. "We remain committed to strengthening our global intellectual property protecti

    9/25/25 8:45:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 12,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/20/25 12:33:35 PM ET
    $AREC
    Coal Mining
    Energy

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 13,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/1/25 1:26:00 PM ET
    $AREC
    Coal Mining
    Energy

    Chief Financial Officer Foster Jonathan P. covered exercise/tax liability with 1,715 shares, bought $100,000 worth of shares (270,270 units at $0.37) and converted options into 7,039 shares, increasing direct ownership by 2,298% to 287,587 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:31 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AIM
    $AREC
    $CNSP
    $GRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Kelly Leanne

    4 - GRI Bio, Inc. (0001824293) (Issuer)

    9/22/25 4:06:10 PM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Szekeres David Leslie

    4 - GRI Bio, Inc. (0001824293) (Issuer)

    9/22/25 4:06:04 PM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Baker David Charles

    4 - GRI Bio, Inc. (0001824293) (Issuer)

    9/22/25 4:05:59 PM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital resumed coverage on American Resources Corp. with a new price target

    D. Boral Capital resumed coverage of American Resources Corp. with a rating of Buy and set a new price target of $6.00

    9/15/25 8:07:21 AM ET
    $AREC
    Coal Mining
    Energy

    Outlook Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Outlook Therapeutics from Buy to Neutral

    8/29/25 8:20:01 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Outlook Therapeutics from Buy to Neutral

    8/28/25 12:48:22 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    SEC Filings

    View All

    Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    9/29/25 5:00:33 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-1 filed by Palisade Bio Inc.

    S-1 - PALISADE BIO, INC. (0001357459) (Filer)

    9/29/25 6:43:54 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Inc. filed SEC Form 8-K: Other Events

    8-K - PALISADE BIO, INC. (0001357459) (Filer)

    9/26/25 5:10:37 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Leadership Updates

    Live Leadership Updates

    View All

    Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

    40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced the appointment of Adriano Treve as a Strategic Advisor for partnerships. With over four decades of experience at Roche, Mr. Treve brings exceptional leadership and a deep understanding of global healthcare markets. He has held senior executive roles across diverse regions, including overseeing U.S. supply c

    7/17/25 8:25:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

    Veteran clinical leader with successful track record and experience to help guide the Company's clinical strategy in Fibrostenotic Crohn's Disease and Ulcerative Colitis Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Emil Chuang, MB BS FRACP to its Board of Directors. Dr. Chuang is a pediatric gastroenterologist with nearly 25 years of pharmaceutical and clinical experience spanning large pharma, biotech, therapeutics, medical nu

    7/9/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

    Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chie

    7/1/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Financials

    Live finance-specific insights

    View All

    Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

    FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treat

    8/28/25 6:30:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

    First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the third quarter of fiscal year 2025 and provided a corporate update. Financial Highlights for the Fiscal Third Quarter Ended June 30, 2025For the fiscal third quarter ended June 30, 2025, Outlook Therapeutics reported net

    8/14/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

    LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. "Outlook Therapeutics remains on track in 2025 to transform into a commercial-stage company with the planned upcoming commercial launch of LYTENAVA™ (bevaciz

    5/15/25 4:01:00 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care